Clearmind Medicine Inc (CMND)

$0.24 -0.14 (-37.83%)
Market Cap 570,000.00
Revenue (ttm) 0.00
Net Income (ttm) -3.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,201,900
Avg Vol 7,399,554
Day's Range N/A - N/A
Shares Out 1.50M
Stochastic %K 2%
Beta 0.87
Analysts Strong Buy
Price Target N/A

Company Profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 536 1016
Address:
1220 West 6th Avenue, Suite 101, Vancouver, Canada
dilatedtrades
dilatedtrades May. 20 at 5:23 AM
$CMND tap hoe?
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 2:17 AM
$WOK (gotta watch this one...) $CNSP $CMND $ONFO $CMND
1 · Reply
nopennys
nopennys May. 20 at 12:21 AM
$GNS $CMND $CYCU $SOAR scam
1 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 12:02 AM
$CMND interesting
0 · Reply
Reesifer
Reesifer May. 19 at 7:57 PM
$CMND added more .2304
0 · Reply
Reesifer
Reesifer May. 19 at 7:54 PM
$CMND added .2316 2 more days for r/s
0 · Reply
SkyLonger
SkyLonger May. 19 at 7:09 PM
$CMND or not ...POS RS COMPANY CEO should be on watch!!
0 · Reply
TwongStocks
TwongStocks May. 19 at 6:44 PM
$CMND Equity Corporate Actions Alert #2026 - 340 Information Regarding the Reverse Stock Split and CUSIP Number Change for Clearmind Medicine Inc. (CMND) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-340 Clearmind Medicine Inc. (CMND) will effect a one-for-ten (1-10) reverse split of its Common Shares. The reverse stock split will become effective on Thursday, May 21, 2026. In conjunction with the reverse split, the CUSIP number will change to 185053600.
0 · Reply
Sophhh
Sophhh May. 19 at 6:03 PM
$CMND oh my what happened here
0 · Reply
Bat_shtt_crazy
Bat_shtt_crazy May. 19 at 5:44 PM
$CMND I’m going to post the name and number of the person at Nasdaq that we can reach out to and complain and hopefully get these crooks delisted. They are giving these multiple RS companies the boot. I recommend blowing up his email. These ass holes are crooks! Will post tomorrow when I find his contact information
0 · Reply
Latest News on CMND
Clearmind Medicine announces 1-for-10 reverse share split

2026-05-19T10:10:36.000Z - 19 hours ago

Clearmind Medicine announces 1-for-10 reverse share split

Clearmind Medicine Announces 1-for-10 Reverse Share Split

May 19, 2026, 6:00 AM EDT - 19 hours ago

Clearmind Medicine Announces 1-for-10 Reverse Share Split

Clearmind Medicine signs new research agreement with Yissum Research Development

2026-05-18T13:00:08.000Z - 1 day ago

Clearmind Medicine signs new research agreement with Yissum Research Development

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

May 18, 2026, 8:42 AM EDT - 1 day ago

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

May 15, 2026, 8:35 AM EDT - 4 days ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

May 12, 2026, 8:41 AM EDT - 7 days ago

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

May 11, 2026, 7:55 AM EDT - 8 days ago

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Clearmind Medicine files European patent application for psychedelic compounds

2026-05-05T12:59:55.000Z - 14 days ago

Clearmind Medicine files European patent application for psychedelic compounds

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

May 5, 2026, 8:50 AM EDT - 14 days ago

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Clearmind Medicine files to sell 22.63M common shares for holders

2026-04-30T21:03:58.000Z - 19 days ago

Clearmind Medicine files to sell 22.63M common shares for holders

Clearmind Medicine Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 19 days ago

Clearmind Medicine Registration statement: Registration filing

Clearmind announces evaluation of CMND-100 for breakthrough therapy designation

2026-04-27T11:48:40.000Z - 22 days ago

Clearmind announces evaluation of CMND-100 for breakthrough therapy designation

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Apr 27, 2026, 7:41 AM EDT - 22 days ago

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Apr 20, 2026, 4:03 PM EDT - 4 weeks ago

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Apr 20, 2026, 7:15 AM EDT - 4 weeks ago

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind announces DSMB recommendation to continue CMND-100 trial

2026-04-16T15:26:52.000Z - 4 weeks ago

Clearmind announces DSMB recommendation to continue CMND-100 trial

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Clearmind Medicine announces CMND-100 meets primary endpoint

2026-04-14T11:40:10.000Z - 5 weeks ago

Clearmind Medicine announces CMND-100 meets primary endpoint

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Apr 14, 2026, 7:32 AM EDT - 5 weeks ago

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine completes treatment, follow-up in CMND-100 trial

2026-03-30T13:25:28.000Z - 7 weeks ago

Clearmind Medicine completes treatment, follow-up in CMND-100 trial

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Mar 30, 2026, 8:32 AM EDT - 7 weeks ago

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind files patent application in India for psychedelic-based compounds

2026-03-27T11:51:31.000Z - 7 weeks ago

Clearmind files patent application in India for psychedelic-based compounds

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Mar 27, 2026, 7:32 AM EDT - 7 weeks ago

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine reports successful ongoing treatment in CMND-100 trial

2026-03-19T12:56:01.000Z - 2 months ago

Clearmind Medicine reports successful ongoing treatment in CMND-100 trial

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 19, 2026, 8:45 AM EDT - 2 months ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 17, 2026, 9:15 AM EDT - 2 months ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 7:30 AM EDT - 2 months ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 13, 2026, 7:45 AM EDT - 2 months ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Clearmind Medicine Quarterly report: Q1 2026

Mar 12, 2026, 5:00 PM EDT - 2 months ago

Clearmind Medicine Quarterly report: Q1 2026

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 9:07 AM EDT - 2 months ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 11, 2026, 7:30 AM EDT - 2 months ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 2 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Mar 4, 2026, 7:30 AM EST - 2 months ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 19, 2026, 1:05 PM EST - 3 months ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Clearmind Medicine Registration statement: Registration Filing

Feb 17, 2026, 7:00 AM EST - 3 months ago

Clearmind Medicine Registration statement: Registration Filing

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 9, 2026, 8:17 AM EST - 3 months ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 6, 2026, 7:55 AM EST - 3 months ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Feb 3, 2026, 8:00 AM EST - 3 months ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 20, 2026, 4:20 PM EST - 4 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Clearmind Medicine Annual report: Q4 2025

Jan 20, 2026, 7:00 AM EST - 4 months ago

Clearmind Medicine Annual report: Q4 2025

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Jan 14, 2026, 8:55 AM EST - 4 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 31, 2025, 9:10 AM EST - 4 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 24, 2025, 9:15 AM EST - 5 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 16, 2025, 8:45 AM EST - 5 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 8:32 AM EST - 5 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 12, 2025, 6:32 AM EST - 5 months ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 10, 2025, 4:15 PM EST - 5 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 5, 2025, 5:00 PM EST - 5 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Registration statement: Registration Filing

Dec 5, 2025, 7:00 AM EST - 5 months ago

Clearmind Medicine Registration statement: Registration Filing

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 2, 2025, 7:57 AM EST - 6 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Dec 1, 2025, 8:56 AM EST - 6 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Clearmind Medicine Registration statement: Registration Filing

Nov 26, 2025, 7:00 AM EST - 6 months ago

Clearmind Medicine Registration statement: Registration Filing

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 25, 2025, 7:17 AM EST - 6 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 24, 2025, 8:51 AM EST - 6 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 20, 2025, 6:01 AM EST - 6 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 6 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 18, 2025, 8:56 AM EST - 6 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 17, 2025, 7:55 AM EST - 6 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Nov 13, 2025, 8:54 AM EST - 6 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Nov 12, 2025, 6:25 AM EST - 6 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 10, 2025, 8:07 AM EST - 6 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Nov 6, 2025, 4:02 PM EST - 6 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Nov 5, 2025, 6:55 AM EST - 6 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 30, 2025, 7:55 AM EDT - 7 months ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Oct 28, 2025, 8:08 AM EDT - 7 months ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Oct 27, 2025, 9:22 AM EDT - 7 months ago

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

dilatedtrades
dilatedtrades May. 20 at 5:23 AM
$CMND tap hoe?
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 2:17 AM
$WOK (gotta watch this one...) $CNSP $CMND $ONFO $CMND
1 · Reply
nopennys
nopennys May. 20 at 12:21 AM
$GNS $CMND $CYCU $SOAR scam
1 · Reply
Sw1ngb0t
Sw1ngb0t May. 20 at 12:02 AM
$CMND interesting
0 · Reply
Reesifer
Reesifer May. 19 at 7:57 PM
$CMND added more .2304
0 · Reply
Reesifer
Reesifer May. 19 at 7:54 PM
$CMND added .2316 2 more days for r/s
0 · Reply
SkyLonger
SkyLonger May. 19 at 7:09 PM
$CMND or not ...POS RS COMPANY CEO should be on watch!!
0 · Reply
TwongStocks
TwongStocks May. 19 at 6:44 PM
$CMND Equity Corporate Actions Alert #2026 - 340 Information Regarding the Reverse Stock Split and CUSIP Number Change for Clearmind Medicine Inc. (CMND) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-340 Clearmind Medicine Inc. (CMND) will effect a one-for-ten (1-10) reverse split of its Common Shares. The reverse stock split will become effective on Thursday, May 21, 2026. In conjunction with the reverse split, the CUSIP number will change to 185053600.
0 · Reply
Sophhh
Sophhh May. 19 at 6:03 PM
$CMND oh my what happened here
0 · Reply
Bat_shtt_crazy
Bat_shtt_crazy May. 19 at 5:44 PM
$CMND I’m going to post the name and number of the person at Nasdaq that we can reach out to and complain and hopefully get these crooks delisted. They are giving these multiple RS companies the boot. I recommend blowing up his email. These ass holes are crooks! Will post tomorrow when I find his contact information
0 · Reply
bmoney83
bmoney83 May. 19 at 5:44 PM
$CMND what a piece of garbage. After the RS they will be close to not beingbin compliance again. Suprised they didnt do a 100 to 1
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 19 at 4:39 PM
$CMND this belongs in n OTC didn’t they already do a r/s not that long ago?
0 · Reply
Woodstocks1999
Woodstocks1999 May. 19 at 3:56 PM
$CMND Compliance is so arbitrary. Just do a reverse split. I want to see Wall street destroyed. It would be but for taxpayer bailouts.
0 · Reply
drillingdeep
drillingdeep May. 19 at 3:44 PM
$CMND same thing happened with PBM in February
0 · Reply
thattradeguy_
thattradeguy_ May. 19 at 3:24 PM
$CMND
0 · Reply
PiviotPoint
PiviotPoint May. 19 at 2:59 PM
$ENVB looks just like $CMND chart yesterday be careful looks like the same game plane might be at work.
0 · Reply
SkyLonger
SkyLonger May. 19 at 2:31 PM
$CMND if they want this at $5 post RS ...it will go to .50 before Thursday IMO play accordingly 🤙
0 · Reply
Pegasus_13
Pegasus_13 May. 19 at 2:03 PM
$CMND whomever these pos are, may every cent you make turn into cancer treatment for your families
1 · Reply
bmoney83
bmoney83 May. 19 at 1:27 PM
$CMND need a miracle. We got screwed
0 · Reply
defman
defman May. 19 at 1:18 PM
$CMND Out. 75% loss. Friggin criminals
0 · Reply
MonkeyPlanet
MonkeyPlanet May. 19 at 12:42 PM
$CMND Hope you heard 🥴
0 · Reply
_NotFinancialAdvice_
_NotFinancialAdvice_ May. 19 at 12:39 PM
$CMND This should be illegal. Pump the stock, create new bag holders, then announce a reverse split the very next day. There’s absolutely no good faith business practice in that.
0 · Reply